+ Watch NWBO
on My Watchlist
successful trials immunotherapy
Constant dilution, sketchy relationships
NWBO will present data from DCVAX-direct phase I trial as well as DCVAX-L phase I and II trials. Presentation will demonstrate SIGNIFICANT efficacy for both drugs, pushing stock higher. I estimate $10 - $12 per share.
Stock promotion pump and dump scheme that uses Redchip.com, a known promoter. Is now altering phase 3 studies because the cancer drug efficacy is not as advertised.
Asco abstract will result in increased share price, particularly in the lead-up to the event
helping cancer patients to live longer
Recently approved drug DCVax-L apporved in Germany ahead of phase III trail completion. WIll be allowed to prescribed for 5yr and can be extended. Previous trials point to sustain life span of existing brain cancer tumor patients. See huge upside
EXCELLENT PIPELINE OF ANTI CANCER ..
meet nwbo ONCS
It has break-thru technology
Long-term Northwest shareholders make me think of a particularly dumb herd of wildebeest on the Serengeti. A couple of weeks ago a pride of lions pounced on the Immunocellular wildebeests and tore them to bits. The Northwest wildebeests snorted and paced around for a bit. A few of the smarter ones broke and ran for the forest cover. The rest quickly forgot about what happened to Immunocellular and started grazing again. The lions salivated. The only reason I'd buy a share of Northwest for more than a nickel is because I could sell it right away for a profit. If you told me I was locked up for two years, forget it. Those wildebeest are doomed. I've seen that nature show too many times.
Dendridic immunotherapy is weak.
Work in biotech for 36 yrs and know until phase 3 shows efficacy chances of success are low. However, positive results in phase 2 trials especially with brain cancer is worth the role of the dice. Don't bet the bank, 100 or 200 shares is not too expensive for a potentially significant gain.
Brain, prostate, ovarian cancer vaccines are in late trials.
losing money every quarter, that $1.98M in cash is not going to last much longer...
Reverse split wont keep this stock from crashing.
Technology two decades in the making reaching maturity in the next 24months
The advantages over DNDN are dramatic. It's just a matter of time.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions